Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lumiracoxib.

Asokumar Buvanendran1, Robert Barkin

  • 1Department of Anesthesiology, Rush University Medical Center, Chicago, Illinois 60612, USA. Asokumar@aol.com

Drugs of Today (Barcelona, Spain : 1998)
|March 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of thoracic epidural anesthesia with an erector spinae plane infusion for post-esophagectomy analgesia: a pragmatic retrospective cohort study.

Journal of thoracic disease·2025
Same author

Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mice.

Frontiers in pain research (Lausanne, Switzerland)·2025
Same author

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain.

Pain·2024
Same author

Approaches to neuropathic amputation-related pain: narrative review of surgical, interventional, and medical treatments.

Regional anesthesia and pain medicine·2024
Same author

Comprehensive, Evidence-Based, Consensus Guidelines for Prescription of Opioids for Chronic Non-Cancer Pain from the American Society of Interventional Pain Physicians (ASIPP).

Pain physician·2023
Same author

Selective Inhibition of Na<sub>V</sub>1.8 with VX-548 for Acute Pain.

The New England journal of medicine·2023
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Lumiracoxib, a selective cyclooxygenase-2 inhibitor, effectively relieves pain in various conditions with good tissue distribution and fewer adverse events than NSAIDs. It demonstrates gastrointestinal safety and no increased cardiovascular risk in non-high-risk patients.

Area of Science:

  • Pharmacology
  • Pain Management
  • Drug Development

Background:

  • Lumiracoxib is a selective cyclooxygenase (COX)-2 inhibitor with a unique distribution profile.
  • It offers pain relief for conditions like osteoarthritis, rheumatoid arthritis, and acute pain.

Purpose of the Study:

  • To evaluate the efficacy, safety, and pharmacokinetic properties of lumiracoxib.
  • To compare lumiracoxib's performance against other COX-2 inhibitors and NSAIDs.

Main Methods:

  • Clinical trials were conducted to assess lumiracoxib's effectiveness in osteoarthritis, acute pain, and postoperative pain.
  • The TARGET study specifically evaluated gastrointestinal safety and cardiovascular events over one year.

Main Results:

Related Experiment Videos

  • Lumiracoxib demonstrated equal efficacy to other COX-2 inhibitors and NSAIDs.
  • Patients experienced significantly fewer adverse events and better tolerability compared to NSAIDs.
  • The TARGET study confirmed gastrointestinal safety and no increased cardiovascular events in non-high-risk patients.

    • Conclusions:

    • Lumiracoxib is an effective and well-tolerated option for managing various pain conditions.
    • Its unique pharmacokinetic profile allows for sustained COX-2 inhibition at inflamed sites.
    • While generally safe, regulatory agencies have issued a black box warning, necessitating careful consideration of its use.